Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation

J Int Med Res. 2018 Jan;46(1):533-537. doi: 10.1177/0300060517720099. Epub 2017 Jul 21.

Abstract

Disseminated intravascular coagulation (DIC) is a commonly encountered clinical situation characterized by thrombotic occlusion or bleeding in patients with lung cancer. DIC in patients with cancer is usually asymptomatic, taking a chronic form as a compensatory mechanism. Although acute DIC in patients with lung cancer is rarely reported, it can be fatal. We herein describe a patient with lung adenocarcinoma with an activating mutation of the epidermal growth factor receptor (EGFR) gene who developed acute DIC after minor surgical excision. The patient's condition dramatically improved immediately after administration of erlotinib. This report alerts physicians to the occurrence of acute DIC and serves as a reference in treating EGFR mutation-positive lung cancer in patients with DIC.

Keywords: Disseminated intravascular coagulation; epidermal growth factor receptor; erlotinib; non-small-cell lung cancer; surgical excision; tyrosine kinase inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnostic imaging
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics
  • Adenocarcinoma / surgery
  • Adenocarcinoma of Lung
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Basal Cell / diagnostic imaging
  • Carcinoma, Basal Cell / drug therapy*
  • Carcinoma, Basal Cell / genetics
  • Carcinoma, Basal Cell / surgery
  • Disseminated Intravascular Coagulation / diagnostic imaging
  • Disseminated Intravascular Coagulation / drug therapy*
  • Disseminated Intravascular Coagulation / genetics
  • Disseminated Intravascular Coagulation / surgery
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics*
  • Erlotinib Hydrochloride / therapeutic use*
  • Gene Expression
  • Humans
  • Lung Neoplasms / diagnostic imaging
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / surgery
  • Male
  • Mutation
  • Protein Kinase Inhibitors / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Erlotinib Hydrochloride
  • EGFR protein, human
  • ErbB Receptors